NCT04597164 is a clinical trial of Artificial liver support system in Hepatitis B, Chronic, sponsored by Third Affiliated Hospital, Sun Yat-Sen University.

Who is sponsoring NCT04597164?

NCT04597164 is sponsored by Third Affiliated Hospital, Sun Yat-Sen University.

What drugs are being tested in NCT04597164?

Interventions in NCT04597164: Artificial liver support system.

What condition does NCT04597164 study?

NCT04597164 studies Hepatitis B, Chronic, Acute-On-Chronic Liver Failure.

Is NCT04597164 still recruiting?

NCT04597164 is currently recruiting now. Last updated 29 November 2024.

Last reviewed 2024-11-29 · How we verify

NCT04597164

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Combination of DPMAS and Low Volume PE for Patients With HBV Related ACLF

Recruiting now Last updated 29 November 2024

What this trial tests

trial testing Artificial liver support system in Hepatitis B, Chronic in 200 participants. Currently enrolling.

Timeline

22 December 2020

Primary endpoint
31 December 2024

31 December 2024

Quick facts

Lead sponsor	Third Affiliated Hospital, Sun Yat-Sen University
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	200
Start date	22 December 2020
Primary completion	31 December 2024
Estimated completion	31 December 2024
Sites	1 location across China

Drugs / interventions tested

Artificial liver support system

Conditions studied

Hepatitis B, Chronic — all drugs for Hepatitis B, Chronic →
Acute-On-Chronic Liver Failure — all drugs for Acute-On-Chronic Liver Failure →

Sponsor

Third Affiliated Hospital, Sun Yat-Sen University

Who can join

Adults 18 to 65, any sex, with Hepatitis B, Chronic or Acute-On-Chronic Liver Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is to investigate investigate the safety and efficacy of Double plasma molecular adsorption system with sequential low-dose plasma exchange in treating hepatitis B virus-related acute-on-chronic liver failure.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Liver cirrhosis and immune dysfunction.
Hasa E, Hartmann P, Schnabl B. · · 2022 · cited 44× · PMID 35792761 · DOI 10.1093/intimm/dxac030
Safety and efficacy of double plasma molecular adsorption system with sequential low-volume plasma exchange in intermediate-stage hepatitis B virus-related acute-on-chronic liver failure.
Xu W, Zhu S, Yang L, Li Z, et al · · 2023 · cited 20× · PMID 36897008 · DOI 10.1002/jmv.28650
Efficacy and safety of combination treatment of double plasma molecular adsorption system and low volume plasma exchange for patients with hepatitis B virus related acute-on-chronic liver failure: a multicentre randomised controlled clinical trial.
Xu W, Li Y, Wang L, Gao H, et al · · 2021 · cited 8× · PMID 34907041 · DOI 10.1136/bmjopen-2020-047690
Double Plasma Molecular Adsorption System with Sequential Low-dose Plasma Exchange in Patients with Hepatitis B Virus-related Acute-on-chronic Liver Failure: A Prospective Study.
Wang L, Xu W, Zhu S, Lin G, et al · · 2023 · cited 7× · PMID 37408804 · DOI 10.14218/jcth.2022.00254
Novel Therapeutic Approaches in Treatment of Acute-on-Chronic Liver Failure.
Saeidinejad M, Elshabrawi A, Sriphoosanaphan S, Andreola F, et al · · 2023 · cited 5× · PMID 38101419 · DOI 10.1055/s-0043-1776773

Verify or expand the search:

Other recruiting trials for Hepatitis B, Chronic

Currently open trials in the same condition.

NCT07370207 — Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific Region · Phase 2 · recruiting
NCT06550622 — Improved Sensitivity Detection of Serum HBsAg and HBsAg Reversion · recruiting
NCT06550128 — Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB). · Phase 2 · active not recruiting
NCT06525909 — A Real-world Study of Staging and Grading of Clinical Immune Status in Chronic Hepatitis B · recruiting
NCT05937178 — Real-world Study Optimizing Nucleotide-analogues · recruiting

Other Third Affiliated Hospital, Sun Yat-Sen University trials

Trials by the same sponsor.

NCT07409259 — PT-MSCs Exosome Injection in the Treatment of Chronic-to-acute Liver Failure · EARLY_PHASE1 · active not recruiting
NCT07281664 — Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hep · NA · not yet recruiting
NCT07338552 — Effectiveness of a Virtual Health Management Community (VHMC) for Pre-diabetes in China · NA · not yet recruiting
NCT07354997 — Establishing a Virtual Health Community Management Model for Pre-Diabetes Patients · NA · completed
NCT07253233 — Treatment of Spinal Cord Injury Using Autologous Concentrated Growth Factors · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04597164 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Third Affiliated Hospital, Sun Yat-Sen University
Last refreshed: 29 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04597164.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing